ACE and COVID-19: Other researchers suggested that ARB might be superior to ACEI for the treatment of hypertensive COVID-19 patients, because ACEIs do not inhibit non-ACE-mediated Ang II production, ACE-induced BK may instigate acute respiratory disease syndrome, and ARB alleviates sputa production and inflammation and attenuates lung fibrosis [10,33].